Authors

Latest:

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Lauren C. Harshman, MD1

Latest:

The Therapeutic Landscape of Metastatic Renal Cell Carcinoma in 2012

In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.

Lauren C. Pinter-Brown, MD,

Lauren C. Pinter-Brown, MD, UCI Health

Lauren C. Pinter-Brown, MD, UCLA

Lauren Carcas, MD

Latest:

Dr. Carcas on the Design and Findings of CONTROL Trial in HER2+ Breast Cancer

Lauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx).

Lauren Ettlinger

Lauren Green

Latest:

Web-Based Exercises Effective in Improving Cognitive Impairment Following Chemotherapy

Patients with symptoms of cognitive impairment who practiced web-based memory and mental processing exercises over a period of 15 weeks experienced marked improvement in their cognitive function.

Lauren M. Green

Latest:

Nivolumab Alone or With Ipilimumab Controls Disease, Extends Survival, in Mesothelioma

Nivolumab as monotherapy or in combination with ipilimumab may present a new second- or third-line treatment option for patients with malignant pleural mesothelioma, based on preliminary findings from a phase II trial where nivolumab alone or in the combination improved disease control and prolonged survival in patients with this rare but aggressive cancer.

Lauren Mays Weddle, PhD

Latest:

Hepatocellular Carcinoma Surveillance in Focus

Controversy over optimal surveillance methods for hepatocellular carcinoma continues to drive ongoing investigation into improved biomarkers and imaging techniques.

Lauren Nye, MD

Latest:

Dr Nye on Paradigm Shifts in the Management of HR+ Breast Cancer

Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.

Lauren Pinter-Brown, MD

Latest:

Dr. Pinter-Brown Discusses Treatment Decisions for CTCL

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma.

Lauren Zoeller

Latest:

Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRC

Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding

Laurence Albiges, MD

Latest:

Dr. Albiges on Next Steps for Immunotherapy in RCC

Laurence Albiges, MD, &lrm;medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

Laurence Albiges, MD, PhD

Latest:

Summary and Forward Looking for RCC

In her concluding remarks, Laurence Albiges, MD, PhD, shares her final thoughts and expresses optimism for the future landscape of renal cell carcinoma treatments.

Laurence J. Heifetz, MD

Latest:

Dr. Heifetz Discusses Rural Oncology Care

Laurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.

Laurie E. Gaspar, MD

Latest:

Dr. Gaspar on a Physician Survey on Prophylactic Cranial Irradiation in SCLC

Laurie E. Gaspar, MD, professor, Radiation Oncology, University of Colorado Denver, discusses a survey she conducted for physicians on the use of prophylactic cranial irradiation for patients with limited small cell lung cancer.

Laurie Gaspar, MD

Latest:

Dr. Gaspar on Treating Brain Metastases in Lung Cancer

Laurie Gaspar, MD, professor and chair of the Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the treatment of brain metastases in patients with lung cancer.

Laurie H. Sehn, MD, MPH

Latest:

Future Directions and Unmet Needs in Relapsed/Refractory MCL

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Laurie H. Sehn, MD, MPH, BC Cancer